International strategy

Advance into the United States, realize the dual reporting of core products in China and the United States,
and firmly practice the "Microdiag of the world”

Project name	Core technologies
AD early screening	Neuro-derived exosome blood test, completed research and development, ready to apply for US breakthrough medical device certification
Covid-19 nucleic acid self-test	NuRapid new technology, similar to US Cue Health, declares US EUA as a US company
Pneumonia in children Streptococcus	Develop home or community testing with NuRapid technology for nucleic acid rapid testing, and plan to apply for US breakthrough medical device certification
New products of exosomes	Exosomal prostate cancer (blood test, urine test)	The product series of tissue-specific exosomes will gradually apply for registration certificates in China, the United States and the European Union.
	Exosomal bowel cancer
	Exosomal liver cancer
	Exosomal breast cancer
	Exosome lung cancer

Swipe to see full table

Go abroad, enter the United States,
It is the dream and expectation that the Microdiag people have been sticking to for 12 years;

In 5 years, Microdiag entered the first-tier market in the United States and obtained original international recognition and interest premium.

Advance into the United States, realize the dual reporting of core products in China and the United States, and firmly practice the "Microdiag of the world”

Advance into the United States, realize the dual reporting of core products in China and the United States,
and firmly practice the "Microdiag of the world”